The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
COVID-19 and liver diseases, what we know so far
World J Clin Cases. 2022 May 6;10(13):3969-3980.doi: 10.12998/wjcc.v10.i13.3969.
1Department of Internal Medicine, University of Nevada Reno School of Medicine, Reno, NV 89052, United States. mohamed.elnaggar.md@gmail.com.
2Department of Internal Medicine, The Brooklyn Hospital Center, Brooklyn, NY 11200, United States.
3Department of Internal Medicine, University of Connecticut, Farmington, CT 06030, United States.
4Department of Internal Medicine, University of Kentucky, Lexington, KY 40508, United States.
5Department of Cardiology, St Joseph's University Medical Center, Paterson, NJ 07503, United States.
Abstract
Coronavirus disease 2019 (COVID-19) pneumonia outbreak started in December 2019. On March 12, 2020, the World Health Organization (WHO) declared that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) constitutes a pandemic, and as of May 2021, SARS-CoV-2 has infected over 167.3 million patients, including 3.4 million deaths, reported to WHO. In this review, we will focus on the relationship between SARS-CoV-2 infection and the liver. We will discuss how chronic liver diseases affect the COVID-19 disease course and outcomes. We will also discuss the SARS-CoV-2 effects on the liver, mechanisms of acute liver injury, and potential management plans.